Coeptis Therapeutics Holdings Inc. - COEP STOCK NEWS

Coeptis Therapeutics (NASDAQ: COEP) has engaged Shareholder Intelligence Services (ShareIntel) for a comprehensive 12-month agreement to monitor and analyze trading patterns of its common stock. This partnership aims to identify illegal short selling and enhance shareholder protections. ShareIntel's DRIL-Down™ technology will track trading anomalies and provide valuable insights into market activities. Coeptis is committed to safeguarding shareholder interests and preventing market manipulation, according to CEO Dave Mehalick. The collaboration is part of Coeptis's broader strategy to protect its stock's value while advancing its cancer treatment platforms.

Coeptis Therapeutics has announced a sponsored research agreement with the University of Pittsburgh to advance the pre-clinical development of SNAP-CAR T cells targeting HER2-positive cancers. This collaboration aims to enable the filing of an Investigational New Drug (IND) application for clinical trials involving SNAP-CAR therapies. HER2 is overexpressed in about 28% of ovarian cancer tissues and 25% of breast cancer patients. The research will be led by Dr. Jason Lohmueller and Dr. Alexander Deiters, with the objective of optimizing SNAP-CAR's application in oncology, potentially offering breakthroughs in treatment options for solid tumors.

Coeptis Therapeutics (NASDAQ: COEP) has announced a strategic collaboration with IQVIA to advance its SNAP-CAR technology, a universal CAR T cell therapy platform. The partnership aims to identify target indications and initiate Investigational New Drug (IND) enabling activities for SNAP-CAR, which can be adapted for various cancer types, including hematologic and solid tumors. Coeptis plans to launch a first-in-human clinical program for SNAP-CAR, emphasizing its potential to treat cancers less accessible with current therapies. The collaboration leverages IQVIA's expertise to streamline the development process.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced that its management will ring the Nasdaq Opening Bell on Nov. 16, 2022. CEO Dave Mehalick expressed excitement about the event, marking the completion of their business combination with Bull Horn Holdings Corp. The company aims to lead in cell therapy technologies for cancer, particularly through their SNAP-CAR platform and a new cell therapy targeting CD38-related cancers. Coeptis is also partnering with VyGen-Bio and researchers at the Karolinska Institutet to develop additional therapies and diagnostics.

Coeptis Therapeutics (NASDAQ: COEP) announced that its Scientific Advisory Board members, Hans-Gustaf Ljunggren and Evren Alici, participated in the Immuno Oncology Talks podcast discussing Natural Killer (NK) Cells. The company focuses on innovative cancer therapies, significantly featuring the CD38-GEAR-NK platform and CD38-Diagnostic tool, co-developed with VyGen-Bio and Karolinska Institutet. Company President David Mehalick highlighted the expertise of these board members as crucial in advancing Coeptis' commitment to effective cancer treatments.

Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) announced the appointment of new directors to its Board following its merger with Bull Horn Holdings. The Board has expanded to seven members, including four independent directors. Key individuals include CEO Dave Mehalick and newly appointed members with diverse expertise in business and clinical development. This restructuring aligns with the company’s focus on advancing its cell therapy technologies, such as SNAP-CAR, aimed at treating various cancers, and reflects its commitment to becoming a leader in innovative cancer treatments.

Coeptis Therapeutics has entered an exclusive license agreement with the University of Pittsburgh for the SNAP-CAR technology, allowing for a programmable CAR T cell therapy targeting multiple cancer antigens. This innovative approach aims to broaden treatment options for hematologic malignancies and solid tumors like breast and ovarian cancer. The SNAP-CAR platform is poised to enhance CAR T therapies by potentially reducing toxicity and addressing cancer relapse, marking a significant advance in Coeptis' cell therapy product portfolio.

Coeptis Therapeutics has entered into an exclusive option agreement with the University of Pittsburgh for three CAR-T technologies aimed at various cancer treatments, including breast and ovarian cancers. This agreement is a strategic move to enhance Coeptis' portfolio and follows two other significant agreements in the current quarter. The company has until October 29, 2022, to exercise the options, with potential extensions available. CEO Dave Mehalick emphasized the transformative potential these technologies hold for addressing underserved cancer types.

Coeptis Therapeutics, Inc. (OTC PINK: COEP) and Bull Horn Holdings Corp. (Nasdaq: BHSE) have announced a definitive merger agreement, with Coeptis becoming a wholly-owned subsidiary of Bull Horn. The transaction, valued at $175 million, is expected to close in Q3 2022, pending regulatory and shareholder approvals. Coeptis focuses on innovative cell therapy platforms for cancer, including CD38-GEAR-NK and CD38-Diagnostic. David Mehalick will continue as CEO, while Chris Calise joins the Board. The merged entity will be rebranded as Coeptis Therapeutics Holdings, Inc., to list under the ticker symbol 'COEP'.